Skip to main content
PMC home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 1997 Sep;34(9):758–760. doi: 10.1136/jmg.34.9.758

A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid.

C A Smith 1, M Wadelius 1, A C Gough 1, D J Harrison 1, C R Wolf 1, A Rane 1
PMCID: PMC1051062  PMID: 9321764

Abstract

Human arylamine N-acetyltransferase (NAT) activity is determined by two distinct genes, NAT1 and NAT2, and the classical acetylation polymorphism in NAT2 has been associated with a variety of disorders, including lupus erythematosus and arylamine induced cancers. Over 50% of the white population exhibit a slow acetylator phenotype. The genetic basis of the defect has been identified and several DNA based assays are available for genotyping studies. We present here a simplified, rapid PCR based assay for the identification of the major slow acetylator genotypes and validate it using isoniazid as probe drug. This assay was 100% predictive of phenotype. The three genotypes (homozygous mutated, heterozygous, and homozygous rapid) corresponded to a trimodal distribution of Ac-INH/INH metabolic ratios (slow, intermediate, and rapid) without overlapping.

Full text

PDF
758

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bechtel Y. C., Bonaiti-Pellie C., Poisson N., Magnette J., Bechtel P. R. A population and family study of N-acetyltransferase using caffeine urinary metabolites. Clin Pharmacol Ther. 1993 Aug;54(2):134–141. doi: 10.1038/clpt.1993.124. [DOI] [PubMed] [Google Scholar]
  2. Blum M., Demierre A., Grant D. M., Heim M., Meyer U. A. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5237–5241. doi: 10.1073/pnas.88.12.5237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blum M., Grant D. M., McBride W., Heim M., Meyer U. A. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol. 1990 Apr;9(3):193–203. doi: 10.1089/dna.1990.9.193. [DOI] [PubMed] [Google Scholar]
  4. Cascorbi I., Drakoulis N., Brockmöller J., Maurer A., Sperling K., Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet. 1995 Sep;57(3):581–592. [PMC free article] [PubMed] [Google Scholar]
  5. Doll M. A., Fretland A. J., Deitz A. C., Hein D. W. Determination of human NAT2 acetylator genotype by restriction fragment-length polymorphism and allele-specific amplification. Anal Biochem. 1995 Nov 1;231(2):413–420. doi: 10.1006/abio.1995.9978. [DOI] [PubMed] [Google Scholar]
  6. Franke S., Klawitz I., Schnakenberg E., Rommel B., Van de Ven W., Bullerdiek J., Schloot W. Isolation and mapping of a cosmid clone containing the human NAT2 gene. Biochem Biophys Res Commun. 1994 Feb 28;199(1):52–55. doi: 10.1006/bbrc.1994.1192. [DOI] [PubMed] [Google Scholar]
  7. Graf T., Broly F., Hoffmann F., Probst M., Meyer U. A., Howald H. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Eur J Clin Pharmacol. 1992;43(4):399–403. doi: 10.1007/BF02220616. [DOI] [PubMed] [Google Scholar]
  8. Grant D. M. Molecular genetics of the N-acetyltransferases. Pharmacogenetics. 1993 Feb;3(1):45–50. doi: 10.1097/00008571-199302000-00005. [DOI] [PubMed] [Google Scholar]
  9. Hickman D., Risch A., Buckle V., Spurr N. K., Jeremiah S. J., McCarthy A., Sim E. Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem J. 1994 Feb 1;297(Pt 3):441–445. doi: 10.1042/bj2970441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hickman D., Risch A., Camilleri J. P., Sim E. Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants. Pharmacogenetics. 1992 Oct;2(5):217–226. doi: 10.1097/00008571-199210000-00004. [DOI] [PubMed] [Google Scholar]
  11. Hickman D., Sim E. N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem Pharmacol. 1991 Aug 8;42(5):1007–1014. doi: 10.1016/0006-2952(91)90282-a. [DOI] [PubMed] [Google Scholar]
  12. Martínez C., Agúndez J. A., Olivera M., Martín R., Ladero J. M., Benítez J. Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics. 1995 Aug;5(4):207–214. [PubMed] [Google Scholar]
  13. Rothman N., Hayes R. B., Bi W., Caporaso N., Broly F., Woosley R. L., Yin S., Feng P., You X., Meyer U. A. Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males. Pharmacogenetics. 1993 Oct;3(5):250–255. doi: 10.1097/00008571-199310000-00004. [DOI] [PubMed] [Google Scholar]
  14. Smith C. A., Moss J. E., Gough A. C., Spurr N. K., Wolf C. R. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility. Environ Health Perspect. 1992 Nov;98:107–112. doi: 10.1289/ehp.9298107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Svensson J. O., Muchtar A., Ericsson O. Ion-pair high-performance liquid chromatographic determination of isoniazid and acetylisoniazid in plasma and urine. Application for acetylator phenotyping. J Chromatogr. 1985 May 31;341(1):193–197. doi: 10.1016/s0378-4347(00)84027-x. [DOI] [PubMed] [Google Scholar]
  16. Vatsis K. P., Weber W. W., Bell D. A., Dupret J. M., Evans D. A., Grant D. M., Hein D. W., Lin H. J., Meyer U. A., Relling M. V. Nomenclature for N-acetyltransferases. Pharmacogenetics. 1995 Feb;5(1):1–17. doi: 10.1097/00008571-199502000-00001. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES